PharmaFocus Today – Page 8 – media

The number of measles cases in Texas, the United States, has increased to 223

On March 11, local time, the Texas Department of State Health Services reported that a measles outbreak occurred in the southern plains of Texas. Since the end of January this year, 223 cases have been found in the state. Among them, 29 patients have been hospitalized and one school-age child has died. The child was not vaccinated and had no known underlying diseases. The report said that because the disease is highly contagious, more cases may occur in the epidemic area and its surrounding communities. The Texas Department of State Health Services is working with local health departments to investigate the epidemic. Measles is an acute rash respiratory infectious disease caused by the measles virus, which is mainly transmitted through respiratory droplets and aerosols. Within one to two weeks after exposure to the virus, the infected person will have symptoms such as high fever, cough, runny nose, red eyes, tears, ...
- Source: drugdu
- 55
- March 14, 2025
Promote the high-quality development of the biopharmaceutical industry in the Chengdu-Chongqing region

Recently, Jiang Lingfeng, deputy to the National People’s Congress and vice chairman of Zhifei Bio, said in an exclusive interview with the Shanghai Securities News that at this year’s National People’s Congress, he made suggestions on topics such as optimizing the ecology and structure of the biopharmaceutical industry. Solve the dilemma of vaccine companies’ difficulty in collecting payments Public data shows that in the first three quarters of 2024, the average accounts receivable turnover days of listed vaccine companies reached 381 days, an increase of more than 60% over 2022, and the accounts receivable of 11 listed vaccine companies accounted for 107% of their revenue. “Vaccine R&D investment is large, the cycle is long, and the risk is high, requiring a large amount of R&D resources. In recent years, the difficulty of vaccine companies in collecting payments has brought huge pressure on the industry’s capital chain, and the industry’s sustainable ...
- Source: drugdu
- 48
- March 14, 2025
“AI+mRNA” tumor vaccine has made progress. SiliDi Pharmaceutical opened more than 7% higher in the morning.

On the morning of March 12, SiliDi Pharmaceutical Co., Ltd. (01244.HK) opened more than 7% higher. As of press time, it rose 3.33%. On the news front, SiliDi Pharmaceutical Co., Ltd. recently announced that its layout of “AI+mRNA” tumor vaccine has made a breakthrough. The company’s key component of lipid nanoparticles (LNP) for nucleic acid drug delivery, ionizable cationic lipids, has recently applied for PCT patents. It is reported that by using AI to design and screen hundreds of lipid compounds, an ionizable cationic lipid research and development platform has been established for different cell types and organ targeting, and the development of self-developed mRNA tumor vaccine projects has been efficiently coordinated, breaking through delivery technology barriers, improving drug targeting, solving problems such as non-specific tissue distribution, and improving drug development efficiency. SiliDi Pharmaceutical Co., Ltd. is an innovative drug company that has entered the commercialization stage and focuses on ...
- Source: drugdu
- 52
- March 14, 2025
Phase III clinical trial of serum-free rabies vaccine of Aimi Vaccine subsidiary was successful

On March 12, Aimi Vaccine (06660) issued an announcement, announcing that its wholly-owned subsidiary Aimi Honor (Ningbo) Biopharmaceutical Co., Ltd. has completed the Phase III clinical trial of serum-free iterative rabies vaccine and obtained the corresponding production license. The vaccine will be submitted for drug registration, marking a major technological breakthrough in the field of rabies vaccines for the company, and is expected to become the world’s first approved serum-free rabies vaccine. According to the results of the completed Phase III clinical study, the vaccine showed good safety, immunogenicity and immune persistence, and has fully met the preset evaluation standards for clinical trials. At present, there is no serum-free rabies vaccine on the market in the world, and the main products sold in the market are serum rabies vaccines. The serum-free iterative rabies vaccine developed by the company does not contain animal serum, which significantly improves safety and reduces the ...
- Source: drugdu
- 52
- March 14, 2025
Aohua Endoscope, Enters the Medical Robot Industry

Recently, Aohua Endoscope has successfully obtained an invention patent authorization called “Endoscope Trolley and Medical Robot”, with patent application number CN202210369876.8. It is reported that this patent effectively reduces the physical exertion of operators through rich operating functions, which will further enhance the company’s technological advantages in the field of soft endoscopes. As a company with over 30 years of development history, Aohua Endoscope’s product layout covers soft mirrors, hard mirrors, and diagnostic and therapeutic consumables. Its diversified layout from upstream to downstream is continuously enhancing its influence in the industry. 01. Obtained patents for endoscope trolleys and medical robots According to the patent abstract, the present invention provides an endoscope trolley and a medical robot. The endoscope trolley comprises a trolley body, a first telescopic arm, and a second telescopic arm. The trolley body comprises a base and a worktable. The worktable is installed on the base in a ...
- Source: drugdu
- 53
- March 13, 2025
The world’s first! One innovative medical device has obtained FDA breakthrough device certification

Recently, NextBioMedical announced that its absorbable embolic microsphere, Nexsphere-F, has been awarded the “Breakthrough Device” designation by the FDA. At present, Nexsphere-F has been approved for CE, and it is worth mentioning that this product is also the only CE approved microsphere for the treatment of musculoskeletal pain embolism. Innovative technology, breaking through traditional boundaries The Nexsphere-F, which was awarded the breakthrough device this time, is an embolic microsphere with a size of 100-300 μ m that can be quickly absorbed by patients. Its indication is for the treatment of knee osteoarthritis pain in patients who do not respond adequately to conservative non pharmacological treatment and/or analgesics. It is worth mentioning that this product integrates innovative absorbable microsphere technology. When Nexsphere-F is delivered to the patient’s target blood vessel through a 1.7Fr microcatheter, the microspheres will absorb water and expand, thereby achieving precise blockage of the target blood vessel and ...
- Source: drugdu
- 56
- March 13, 2025
So far, my country has never exported fentanyl drugs to North America

On March 12, the spokesperson of the National Medical Products Administration answered reporters’ questions about the white paper “China’s Fentanyl Substance Control” and said that fentanyl drugs are mainly used for analgesia in clinical practice. Non-medical use will cause drug abuse and even lead to public health and social problems. So far, there are 4 fentanyl drugs approved for marketing in my country, namely fentanyl, sufentanil, remifentanil and alfentanil. Three companies are allowed to produce raw materials and five companies are allowed to produce preparations. In 2024, my country’s production of fentanyl raw materials will be 100 kilograms, mainly for domestic medical use and export. In 2024, my country’s fentanyl drug exports will be 12.3 kilograms (in terms of fentanyl bases), mainly exported to South Korea, Vietnam, the Philippines and other countries. To date, my country has never exported fentanyl-related drugs to North America. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 51
- March 13, 2025
Weiming Pharmaceutical plans to sign a sales contract worth 53.978 million yuan

On March 12, Weiming Pharmaceutical announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a “Sales Contract” with Jiangsu Soho Innovation Technology Group Co., Ltd. to purchase the liquid storage system and chromatography system, filler and reaction bags required for the Shandong Weiming Biomedicine Industrial Park project recombinant human nerve growth factor eye drops production workshop from Jiangsu Soho. The total contract price is 53.978 million yuan. The signing of this contract provides hardware guarantee for the industrialization of the company’s existing pipelines, which is conducive to further improving the company’s industrial layout and promoting the continuous growth of the company’s operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 44
- March 13, 2025
Wholly-owned subsidiary Xiantai Pharmaceutical obtains Spanish AEMPS GMP compliance certificate

On March 12, North China Pharmaceutical announced that its wholly-owned subsidiary North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. received the “Manufacturer GMP Compliance Certificate” issued by the Spanish Medicines and Medical Devices Agency. The production lines involved in the certificate include procaine penicillin series products, benzathine penicillin series products and amoxicillin (sterile), and the inspection conclusion is in compliance with EU GMP principles. Among them, the inspection of amoxicillin (sterile) is the first drug GMP compliance inspection before it is listed in the EU. Xiantai Company is the only domestic amoxicillin (sterile) manufacturer that has passed EUGMP certification. The acquisition of this certificate will have a positive impact on the sales of amoxicillin (sterile) products to the EU market, but will not have a significant impact on the company’s current operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 45
- March 13, 2025
The “One who swimming against the current” in the generic drug industry

Centralized procurement has led to a sharp drop in the price of generic drugs, which poses a direct challenge to the company’s revenue. However, key generic drug companies such as Beite Pharmaceuticals have maintained steady revenue growth under the background of centralized procurement with their strong R&D strength and market competitiveness. Data show that its sales of pharmaceutical preparations have continued to grow, with a compound growth rate of up to 30.7%, especially in 2021, which has achieved a leapfrog growth. Remarkable performance and steady growth In recent years, Chengdu Beite Pharmaceuticals’ performance has continued to grow, showing strong development resilience and potential. In 2023, the company’s sales of pharmaceutical preparations reached 7.41 billion yuan. From 2016 to 2023, the compound growth rate of sales of preparations was as high as 30.7%, especially in 2021, Beite Pharmaceuticals’ performance achieved a leapfrog growth, a year-on-year increase of 98.0% compared with 2020. ...
- Source: drugdu
- 39
- March 13, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.